EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Prediagnostic Amino Acid Metabolites and Risk of Gout, Accounting for Serum Urate: Prospective Cohort Study and Mendelian Randomization

Natalie McCormick iD, Amit D Joshi, Chio Yokose iD, Bing Yu, Adrienne Tin iD, Robert Terkeltaub, Tony R Merriman iD, Oana Zeleznik, A Heather Eliassen, Gary C Curhan, Hang-Korng Ea, Matthew Nayor und 2 weitere

Arthritis Care & Research · 2024

DOI: 10.1002/acr.25420 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Arthritis Care & Research, 2024. Verfasst von Natalie McCormick und 13 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital and Harvard Medical School, Boston, and Arthritis Research Canada, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Gout, Mendelian Randomization Analysis, Uric Acid, Amino Acids. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Our objective was to prospectively investigate prediagnostic population‐based metabolome for risk of hospitalized gout (ie, most accurate, severe, and costly cases), accounting for serum urate.

Methods

We conducted prediagnostic metabolome‐wide analyses among 249,677 UK Biobank participants with nuclear magnetic resonance metabolomic profiling (N = 168 metabolites, including eight amino acids) from baseline blood samples (2006–2010) without a history of gout. We calculated multivariable hazard ratios (HRs) for hospitalized incident gout, before and after adjusting for serum urate levels; we included patients with nonhospitalized incident gout in a sensitivity analysis. Potential causal effects were evaluated with two‐sample Mendelian randomization.

Results

Correcting for multiple testing, 107 metabolites were associated with incidence of hospitalized gout (n = 2,735) before urate adjustment, including glycine and glutamine (glutamine HR 0.64, 95% confidence interval [CI] 0.54–0.75, P = 8.3 × 10 −8 ; glycine HR 0.69, 95% CI 0.61–0.78, P = 3.3 × 10 −9 between extreme quintiles), and glycoprotein acetyls (HR 2.48, 95% CI 2.15–2.87, P = 1.96 × 10 −34 ). Associations remained significant and directionally consistent following urate adjustment (HR 0.83, 95% CI 0.70–0.98; HR 0.86, 95% CI 0.76–0.98; HR 1.41, 95% CI 1.21–1.63 between extreme quintiles), respectively; corresponding HRs per SD were 0.91 (95% CI 0.86–0.97), 0.94 (95% CI 0.91–0.98), and 1.10 (95% CI 1.06–1.14). Findings persisted when including patients with nonhospitalized incident gout. Mendelian randomization corroborated their potential causal role on hyperuricemia or gout risk; with change in urate levels of −0.05 mg/dL (95% CI −0.08 to −0.01) and −0.12 mg/dL (95% CI −0.22 to −0.03) per SD of glycine and glutamine, respectively, and odds ratios of 0.94 (95% CI 0.88–1.00) and 0.81 (95% CI 0.67–0.97) for gout.

Conclusion

These prospective findings with causal implications could lead to biomarker‐based risk prediction and potential supplementation‐based interventions with glycine or glutamine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GoutMendelian Randomization AnalysisUric AcidAmino AcidsHumansProspective StudiesMaleFemaleMiddle AgedAgedRisk FactorsMetabolomicsBiomarkersAdultUnited KingdomIncidenceRisk AssessmentHospitalization

Substanzen

Uric AcidAmino AcidsBiomarkers

Autor:innen und Institutionen

  • Massachusetts General Hospital and Harvard Medical School, Boston, and Arthritis Research Canada, Vancouver, British Columbia, Canada.
  • Brigham and Women's Hospital, Boston, Massachusetts.
  • Massachusetts General Hospital and Harvard Medical School, Boston.
  • The University of Texas Health Science Center at Houston.
  • University of Mississippi Medical Center, Jackson.
  • University of California San Diego, La Jolla.

ORCID-Profile: Natalie McCormick, Chio Yokose, Adrienne Tin, Tony R Merriman

Förderung

  • NIAMS NIH HHS
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

McCormick, N., Joshi, A. D., Yokose, C., Yu, B., Tin, A., Terkeltaub, R., Merriman, T. R., Zeleznik, O., Eliassen, A. H., Curhan, G. C., Ea, H. K., Nayor, M., Raffield, L. M., & Choi, H. K. (2024). Prediagnostic Amino Acid Metabolites and Risk of Gout, Accounting for Serum Urate: Prospective Cohort Study and Mendelian Randomization. Arthritis Care & Research. https://doi.org/10.1002/acr.25420

Vancouver

McCormick N, Joshi AD, Yokose C, Yu B, Tin A, Terkeltaub R, et al. Prediagnostic Amino Acid Metabolites and Risk of Gout, Accounting for Serum Urate: Prospective Cohort Study and Mendelian Randomization. Arthritis Care & Research. 2024. doi:10.1002/acr.25420

BibTeX
@article{McCormick2024,
  author = {McCormick, Natalie and Joshi, Amit D and Yokose, Chio and Yu, Bing and Tin, Adrienne and Terkeltaub, Robert and Merriman, Tony R and Zeleznik, Oana and Eliassen, A Heather and Curhan, Gary C and Ea, Hang-Korng and Nayor, Matthew and Raffield, Laura M and Choi, Hyon K},
  title = {Prediagnostic Amino Acid Metabolites and Risk of Gout, Accounting for Serum Urate: Prospective Cohort Study and Mendelian Randomization},
  journal = {Arthritis Care & Research},
  year = {2024},
  doi = {10.1002/acr.25420}
}
Kostenlos starten →